Workflow
南微医学(688029) - 2022 Q3 - 季度财报
MTMMTM(SH:688029)2022-10-27 16:00

Financial Performance - The company achieved operating revenue of RMB 551.81 million in Q3 2022, representing a year-on-year increase of 7.31%[2] - Net profit attributable to shareholders was RMB 102.11 million, a decrease of 2.98% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 97.12 million, an increase of 33.96% year-on-year[2] - The cumulative operating revenue for the first three quarters of 2022 reached RMB 1.51 billion, an increase of 8.87% year-on-year[3] - The company reported a net profit of RMB 226.96 million for the first three quarters, a decrease of 8.68% year-on-year[3] - Total operating revenue for the first three quarters of 2022 reached ¥1,512,101,641.63, an increase of 8.9% compared to ¥1,388,953,773.62 in the same period of 2021[16] - Net profit for the third quarter of 2022 was ¥233,796,364.70, a decrease of 8.9% from ¥256,631,858.18 in the same quarter of 2021[19] - Basic earnings per share for the period were RMB 0.5453, down 3.27% from the same period last year[3] - Earnings per share for the third quarter of 2022 were ¥1.2121, down from ¥1.3313 in the same period last year[20] Assets and Liabilities - The total assets at the end of the reporting period were RMB 3.80 billion, an increase of 4.69% compared to the end of the previous year[3] - As of September 30, 2022, the company's total assets reached approximately CNY 3.80 billion, an increase from CNY 3.63 billion at the end of 2021, representing a growth of about 4.6%[13] - The company's total liabilities decreased slightly to CNY 580.33 million from CNY 601.64 million, reflecting a decrease of about 3.5%[14] - The company's total liabilities amounted to ¥635,571,416.04, slightly down from ¥641,444,869.77 in the previous year[18] - The total equity attributable to shareholders reached ¥3,111,701,714.24, an increase from ¥2,943,321,990.43 year-over-year[18] Cash Flow - The cash inflow from operating activities for the first three quarters of 2022 was CNY 1,729,016,599.67, an increase of 21.4% compared to CNY 1,425,075,648.60 in the same period of 2021[21] - The net cash flow from operating activities for the first three quarters of 2022 was CNY 152,130,691.78, a decrease of 13.9% from CNY 176,770,982.80 in the previous year[22] - The total cash inflow from investment activities was CNY 1,545,309,428.47, down 30.8% from CNY 2,234,762,524.59 in the same period of 2021[22] - The net cash flow from investment activities for the first three quarters of 2022 was CNY 48,533,900.03, a significant decrease of 87.4% compared to CNY 384,922,267.04 in 2021[22] - The cash inflow from financing activities was CNY 100,000,000.00, compared to CNY 548,500.00 in the same period of 2021[22] - The net cash flow from financing activities was -CNY 7,608,813.74, an improvement from -CNY 32,311,944.06 in the previous year[22] - The cash and cash equivalents at the end of the period were CNY 1,184,196,317.48, compared to CNY 1,165,289,354.08 at the end of the same period in 2021[23] Research and Development - Research and development expenses totaled RMB 37.90 million, accounting for 6.87% of operating revenue, a decrease of 1.30 percentage points year-on-year[3] - Research and development expenses for the third quarter of 2022 were ¥121,698,108.19, compared to ¥101,025,381.15 in the same quarter of 2021, indicating a growth of 20.5%[18] Inventory and Receivables - Inventory levels increased significantly to CNY 513.17 million, compared to CNY 394.29 million in the previous year, reflecting a rise of about 30.2%[13] - The company's accounts receivable decreased to CNY 330.00 million from CNY 354.95 million, showing a decline of approximately 7.0%[13] Strategic Developments - The company received multiple product registrations in international markets, including Brazil and the United States, for various medical devices, enhancing its product portfolio[12] - The company has introduced new products, including the ProTrap Luma specimen tray and digital controllers, which received registration certificates in Brazil and Germany, respectively[12] - The company plans to expand its market presence through new product launches and potential acquisitions in the upcoming quarters[11] - The company’s gross profit margin is expected to improve due to the introduction of higher-margin products and operational efficiencies[11] Financial Improvements - The company reported a significant reduction in short-term borrowings, which stood at CNY 100 million, indicating a strategic move to lower debt levels[14] - The company received CNY 11,091,453.17 in tax refunds, a significant increase from CNY 336,045.93 in the previous year[21] - The total cash outflow from operating activities was CNY 1,576,885,907.89, an increase of 26.3% compared to CNY 1,248,304,665.80 in 2021[22] - The cash outflow for employee compensation was CNY 475,081,771.99, up 31.3% from CNY 361,757,235.74 in the previous year[22]